Government Accountability Office. Biological Defense: DOD Has Strengthened Coordination on Medical Countermeasures but Can Improve Its Process for Threat Prioritization. Washington, DC: Government Accountability Office; May2014. http://www.gao.gov/products/GAO-14-442. Accessed September10, 2014.
US Department of Defense. Department of Defense Directive 5160.05E: Roles and Responsibilities Associated with the Chemical and Biological Defense (CBD) Program (CBDP). October9, 2008. http://www.dtic.mil/whs/directives/corres/pdf/516005p.pdf. Accessed September10, 2014.
4.
PetroJB, PlasseTR, McNultyJA. Biotechnology: impact on biological warfare and biodefense. Biosecur Bioterror, 2003; 1(3):161-168.
5.
MorganS, GrootendorstP, LexchinJ, CunninghamC, GreysonD. The cost of drug development: a systematic review. Health Policy Amst Neth, 2011Apr; 100(1):4-17.
6.
DiMasiJA, HansenRW, GrabowskiHG. The price of innovation: new estimates of drug development costs. J Health Econ, 2003Mar; 22(2):151-185.
Assistant to the Secretary of Defense for Nuclear Chemical Biological Defense Programs. Chemical and Biological Defense Program (CBDP) Strategic Plan. Washington, DC: Department of Defense; 2012.
9.
PetroJB, CarusWS. Biological threat characterization research: a critical component of national biodefense. Biosecur Bioterror, 2005; 3(4):295-308.
10.
Assistant to the Secretary of Defense for Nuclear Chemical Biological Defense Programs. Chemical and Biological Defense Program (CBDP) Strategic Plan. Washington, DC: Department of Defense; 2008.
11.
United States Commission on the Intelligence Capabilities of the United States Regarding Weapons of Mass Destruction. Report to the President of the United States. Washington, DC: Commission on the Intelligence Capabilities of the United States Regarding Weapons of Mass Destruction; 2005.